Highligths of SABCS 2024

Kate Lathrop, MD discuss some of the high impact, clinically relevant, clinical trials that were presented at the San Antonio Breast Cancer Symposium 2024. The studies discussed: - (01:28) Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib or placebo in patients w/ triple-negative breast cancer or HER2+ BRCA-mutated breast cancer with molecular residual disease after definitive therapy - (07:15) Impact of Anthracyclines in High Genomic Risk Node-Negative HR+/HER2- Breast Cancer - (13:02) No axillary surgery versus axillary sentinel lymph node biopsy in patients with early invasive breast cancer and breast-conserving surgery: Final primary results of the Intergroup-Sentinel-Mamma (INSEMA) trial - (19:10) A Phase 2 Study of Neoadjuvant HER2-targeted Therapy +/- Immunotherapy with Pembrolizumab (neoHIP) Video: https://medicaldigest.org/scientific-contents/interview:highligths-sabcs-2024